Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $34.40

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $34.40.

Several research analysts recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Apogee Therapeutics in a research note on Tuesday, August 8th. They set a “buy” rating and a $34.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, October 11th. TD Cowen initiated coverage on Apogee Therapeutics in a research note on Tuesday, August 8th. They issued an “outperform” rating for the company. Guggenheim began coverage on Apogee Therapeutics in a report on Tuesday, August 8th. They set a “buy” rating and a $29.00 price target on the stock. Finally, William Blair restated an “outperform” rating and set a $40.00 price target on shares of Apogee Therapeutics in a report on Monday, August 28th.

Get Apogee Therapeutics alerts:

Get Our Latest Report on APGE

Institutional Trading of Apogee Therapeutics

An institutional investor recently bought a new position in Apogee Therapeutics stock. SG Americas Securities LLC bought a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,931 shares of the company’s stock, valued at approximately $105,000. Institutional investors and hedge funds own 32.06% of the company’s stock.

Apogee Therapeutics Stock Down 0.5 %

Shares of APGE stock opened at $19.97 on Tuesday. Apogee Therapeutics has a 52-week low of $18.99 and a 52-week high of $25.54. The firm has a fifty day simple moving average of $22.17.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its quarterly earnings data on Monday, August 28th. The company reported ($3.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.49) by ($1.29). As a group, equities research analysts forecast that Apogee Therapeutics will post -2.22 earnings per share for the current year.

Apogee Therapeutics Company Profile

(Get Free Report

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Featured Articles

• Five stocks we like better than Apogee Therapeutics
• What is a Non-Fungible Token (NFT)? Definition and How it Works
• 3 High Dividend Stocks To Beat Treasury Yields
• Trading Halts Explained
• United Airlines Shares Fall Despite Solid Quarter
• Financial Services Stocks Investing
• Housing Starts Up, Homebuilders Down as Mortgage Rates Soar

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.